CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Phase 3

Active, not recruiting

Conditions: Hereditary Angioedema (HAE)

Interventions: Biological: CSL312

First Posted Date: 2023-04-19

Last Posted Date: 2024-12-09

Lead Sponsor: CSL Behring

Target Recruit Count: 20

Registration Number: NCT05819775

Locations: 🇺🇸
Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸
Medical Research of Arizona, Scottsdale, Arizona, United States
🇺🇸
Donald S. Levy M.D., Orange, California, United States

and more 10 locations

Effects of CSL324 in the Lung After Segmental Challenge

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CSL324
Drug: Placebo

First Posted Date: 2022-12-16

Last Posted Date: 2023-11-29

Lead Sponsor: CSL Behring

Target Recruit Count: 40

Registration Number: NCT05653713

Locations: 🇩🇪
Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Phase 3

Terminated

Conditions: Traumatic Injury

Interventions: Drug: BE1116
Drug: Placebo

First Posted Date: 2022-10-06

Last Posted Date: 2024-11-01

Lead Sponsor: CSL Behring

Target Recruit Count: 1370

Registration Number: NCT05568888

Locations: 🇺🇸
UAB Hospital, Birmingham, Alabama, United States
🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸
Chandler Regional Medical Center, Chandler, Arizona, United States

and more 108 locations

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Phase 2

Recruiting

Conditions: Atherosclerotic Cardiovascular Disease
End Stage Kidney Disease

Interventions: Drug: CSL300
Drug: Placebo

First Posted Date: 2022-08-03

Last Posted Date: 2025-01-09

Lead Sponsor: CSL Behring

Target Recruit Count: 2310

Registration Number: NCT05485961

Locations: 🇺🇸
84000228 - National Nephrology Alliance Research - Riverside, Riverside, California, United States
🇺🇸
84000453 - Nephrology Physician's LLC, Mishawaka, Indiana, United States
🇺🇸
84000436 - Hypertension & Nephrology Association, Eatontown, New Jersey, United States

and more 179 locations

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection

Completed

Conditions: Antibody-mediated Rejection in Kidney Transplant

Interventions: Other: Non-Chronic active AMR group
Other: Chronic active AMR group

First Posted Date: 2022-07-11

Last Posted Date: 2023-04-13

Lead Sponsor: CSL Behring

Target Recruit Count: 52

Registration Number: NCT05452317

Locations: 🇺🇸
University of Maryland School of Medicine, Div. of Nephrology, Baltimore, Maryland, United States
🇺🇸
Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸
The Washington University, Saint Louis, Missouri, United States

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

Active, not recruiting

Conditions: Hemophilia B

Interventions: Genetic: AAV5-hFIX

First Posted Date: 2022-05-04

Last Posted Date: 2025-01-07

Lead Sponsor: CSL Behring

Target Recruit Count: 9

Registration Number: NCT05360706

Locations: 🇩🇪
Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet, Frankfurt, Germany
🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands

and more 3 locations

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: CSL312

First Posted Date: 2022-04-01

Last Posted Date: 2022-10-06

Lead Sponsor: CSL Behring

Target Recruit Count: 132

Registration Number: NCT05306275

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: Garadacimab

First Posted Date: 2021-11-23

Last Posted Date: 2024-12-13

Lead Sponsor: CSL Behring

Target Recruit Count: 81

Registration Number: NCT05130970

Locations: 🇺🇸
Central Florida Pulmonary Group, PA, Orlando, Florida, United States
🇪🇸
Hospital Universitario Puerta del Mar (HUPM), Cadiz, Spain
🇦🇹
Kepler Universitätsklinikum, Linz, Austria

and more 44 locations

Observatory of Patients With Haemophilia B Treated by IdElvion®

Active, not recruiting

Conditions: Haemophilia B

First Posted Date: 2021-10-21

Last Posted Date: 2025-01-08

Lead Sponsor: CSL Behring

Target Recruit Count: 222

Registration Number: NCT05086575

Locations: 🇫🇷
CHU Amiens - Picardie, Amiens, France
🇫🇷
CH Annecy Genevois, Annecy, France
🇫🇷
CHRU Besançon, Besançon, France

and more 25 locations

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Phase 3

Active, not recruiting

Conditions: Hereditary Angioedema

Interventions: Biological: CSL312

First Posted Date: 2021-02-04

Last Posted Date: 2025-01-09

Lead Sponsor: CSL Behring

Target Recruit Count: 171

Registration Number: NCT04739059

Locations: 🇨🇦
Gordon Sussman Clinical Research, Toronto, Ontario, Canada
🇭🇺
Semmelweis Egyetem Altalanos Orvostudományi Kar Belgyógyászati és Hematológiai Klinika, Budapest, Hungary
🇨🇦
McMaster University, Hamilton, Ontario, Canada

and more 41 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy